 |
|
Recombinant Human Erythropoietin Therapy for a Jehovah's Witness Child With Severe Anemia due to Hemolytic-Uremic Syndrome
Da Eun Woo (Woo DE), Jae Min Lee (Lee JM), Yu Kyung Kim (Kim YK), Yong Hoon Park (Park YH)
Clin Exp Pediatr. 2016;59(2):100-103. Published online 2016 Feb 29 DOI: https://doi.org/10.3345/kjp.2016.59.2.100
|
|
Citations to this article as recorded by
 Outcomes of perioperative management in Jehovah's Witness patients undergoing surgeries with a risk of bleeding: a retrospective, single-center, observational study
Keum Young So, Sang Hun Kim
Medical Biological Science and Engineering.2022; 5(1): 6. CrossRef Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial
Alejandro Balestracci, Marina Andrea Capone, Luciana Meni Battaglia, Ismael Toledo, Sandra Mariel Martin, Laura Beaudoin, Jeanette Balbaryski, Lorena Gómez
Pediatric Nephrology.2022; 37(10): 2383. CrossRef Targeting the innate repair receptor axis via erythropoietin or pyroglutamate helix B surface peptide attenuates hemolytic-uremic syndrome in mice
Sophie Dennhardt, Wiebke Pirschel, Bianka Wissuwa, Diana Imhof, Christoph Daniel, Jan T. Kielstein, Isabel Hennig-Pauka, Kerstin Amann, Florian Gunzer, Sina M. Coldewey
Frontiers in Immunology.2022;[Epub] CrossRef Refusal of blood transfusion by a hemodialysis patient with renal anemia for religious reasons
Honami Honjoh, Fumihiro Takeguchi, Miho Kato, Sho Rinno, Atsuko Nagashima, Susumu Sakurai, Kanna Watanabe, Yoshitaka Miyaoka, Yume Nagaoka, Yoshihiko Kanno
Nihon Toseki Igakkai Zasshi.2018; 51(6): 409. CrossRef
|